

Low-Dose Pioglitazone is Beneficial in Patients with the Metabolic Syndrome.

Vu A, et al. Pharmacotherapy. 2016; 36(3): 252-62.

- A randomized, double-blind study was conducted in the US to determine the effects of low-dose pioglitazone (7.5 mg daily for 8 weeks) on plasma adipocyte-derived cytokines and insulin sensitivity in 32 adults with metabolic syndrome (without diabetes mellitus).
- Pioglitazone increased levels of the adipocyte-derived cytokine adiponectin, which significantly correlated with improved insulin sensitivity.

Low-dose pioglitazone favorably modulates plasma adiponectin, which was associated with improved insulin sensitivity in patients with the metabolic syndrome without diabetes.